NEOGEN CORP (NEOG)
Health Care · Food and Animal Safety Diagnostics · NASDAQ
Neogen is a global provider of diagnostics and biosecurity solutions dedicated to ensuring the safety and quality of the world's food and animal supply.
What NEOGEN CORP does
Neogen Corporation provides diagnostic test kits, services, and software focused on food and animal safety. Its Food Safety segment offers solutions for detecting foodborne pathogens, allergens, and spoilage organisms, while its Animal Safety segment supplies veterinary instruments, pharmaceuticals, genomics testing, and biosecurity products. The company serves food and feed producers, veterinary professionals, and laboratories globally.
Recent developments
In the Q1 fiscal 2027 earnings release, the company reported revenue growth of 6.5% and raised its fiscal year 2027 guidance. It remains on track to begin a planned multi-quarter manufacturing transition for its Petrifilm product line in November 2026.
From NEOGEN CORP's filing of 2026-10-06.
Themes: food safety diagnostics, animal health and genomics, biosecurity, food supply chain integrity, pathogen detection
Fundamentals
- Price$11.71 as of 2026-10-08 close
- Market cap$2.6B as of 2026-08-31 (share count; price 2026-10-08)
- 1-year return+101.2% 2025-10-08 close $5.82 → 2026-10-08 close $11.71
- P/En/a negative earnings
- Net margin-0.9% FY2026, SEC XBRL
- Gross margin+46.9% FY2026, SEC XBRL
- ROE-0.4% FY2026, SEC XBRL
- Debt / equity0.38 as of 2026-09-03
- Revenue growth (YoY)-2.7% as of 2026-09-03
- Revenue CAGR (3y)+1.9% SEC XBRL
- Beta0.31 as of 2026-09-03
- Last reported earnings2026-10-06 SEC EDGAR Form 8-K (Item 2.02)
How NEOG compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NEOG is not currently in any published Top 10 list. Its scores are below.
Top 10 score
42.4 #1111 of 1,379 scored · #128 of 151 in Health Care
Valuation 88th (price to book 1.2) and trend 66th (over the past 12 months this stock beat the market by 86.2 percentage points); weakest is profitability (15th, operating margin -2.5%, return on equity -0.4%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How NEOGEN CORP looks technically
NEOGEN CORP (NEOG) is trading 16.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 203 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 17.9% below its highest point of the past year. Trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 16.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +16.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.12 | $12.12 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.06 | $10.06 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 14.26. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 203 trading days ago — a "golden cross", a bullish long-term signal | 203 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control | 31.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($11.13 to $14.26) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.26 | $14.26 |
|---|---|---|
| From the 52-week high | it is 17.9% below its 52-week high (its highest price of the past year) | -17.9% |
| Above the 52-week low | it is 118.1% above its 52-week low (its lowest price of the past year) | +118.1% |
| Below the 52-week high | it is 17.9% below its highest point of the past year | 17.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $48.75 (set on 2021-04-21) | $48.75 |
| Given back of the 52-week move | over the past year its closes ranged ($5.41 to $13.98), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.41 to $8.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.5% |
| From the all-time high | it is 76.0% below its all-time high | -76.0% |
| Nearest price level | it is trading 2.3% above a support level at $11.44 — a price it turned at three times since 2024-12-18, most recently on 2026-09-04. Since 2024-10-08 it has 14 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.3% |
| All-time low | its lowest closing price on record is $1.50 (set on 2005-07-12) | $1.50 |
| Above the all-time low | it is 680.5% above its all-time low | +680.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7215 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7215 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.25 and $14.24 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.25 – $12.75 – $14.24 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (16.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest | 2.07× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.0% since the prior reading | +5.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.5% |
|---|---|---|
| Open gap | it gapped 11.7% above the previous close 49 sessions ago and has not traded back through the level it left behind at 9.4 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +11.7% |
| Gap filled | a 5.4% gap up opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.6 percentage points (the stock lost 1.5% while the market gained 1.0%) | -2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 22.6 percentage points (the stock gained 26.5% while the market gained 3.8%) | +22.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 5.0 percentage points (the stock gained 22.5% while the market gained 17.5%) | +5.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 86.2 percentage points (the stock gained 101.2% while the market gained 15.0%) | +86.2% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.1% of the share price. | +3.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.45 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +12.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-07-30 (its 10-K), so the typical buyer over that stretch is under water. That average is $12.34 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -5.1% |
Price levels it has turned at before
NEOG last closed at $11.71 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.44 | Support | 2.3% below the last close | turned there three times · 2024-12-18 to 2026-09-04 |
| $10.73 | Support | 8.3% below the last close | turned there three times · 2025-01-16 to 2026-04-09 |
| $10.40 | Support | 11.2% below the last close | turned there four times · 2025-02-24 to 2026-07-16 |
| $13.47 | Resistance | 15.0% above the last close | turned there twice · 2024-10-25 to 2025-01-07 |
| $14.35 | Resistance | 22.5% above the last close | turned there twice · 2024-11-15 to 2026-09-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $14.26.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Unusually heavy trading volume · Broke down to a new 20-day low · Analyst price target recently RAISED · beating the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$14.00 range $14.00 – $14.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NEOG
- Consensus EPS estimate$0.05333 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 from $0.05333, on 2026-08-29, 36-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Integration risks from the 3M Food Safety business acquisition and associated manufacturing transitions.","Dependence on third-party suppliers and potential disruptions from global trade, tariffs, and inflation.","Risks associated with international operations, including geopolitical tensions and currency fluctuations."]
What changed in the latest 10-Q
AI-assisted comparison of NEOG's 10-Q filed 2026-04-09 against the prior one filed 2026-01-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states that fiscal year 2026 experienced elevated inventory write-offs, whereas older filing limited this to fiscal year 2025 and particularly the fourth quarter
- Newer filing extends the description of production inefficiencies to 'throughout fiscal year 2026, albeit with continued improvement in each successive quarter' rather than older filing's 'continued in first half of fiscal year 2026'
- Newer filing specifies geopolitical tensions 'such as eastern Europe and the Middle East' rather than older filing's non-specific 'ongoing geopolitical tensions in certain regions'
- Newer filing adds statement that 'there have been signs of sequential improvement from prior quarters and expectations for growth in calendar year 2026' followed by 'As a result, we expect steadily increasing growth rates in this market'
- Newer filing includes reference to 'the announced divestiture of the genomics business' in the forward-looking statements risk factors
- Newer filing text appears truncated mid-sentence regarding Animal Safety segment issues in third quarter of fiscal year 2026
- Removed:
- Older filing contained statement 'Neogen does not provide forecasts of future financial performance' which does not appear in newer filing
- Older filing's forward-looking statement risk factors referencing 'the continued integration of the 3M food safety business and the realization of the expected benefits from that acquisition' and 'the relationship with and performance of our transition manufacturing partner' are replaced with broader language in newer filing
- Older filing's risk factors included 'our ability to adequately and timely remediate certain identified material weaknesses in our internal control over financial reporting' which does not appear in newer filing
- Older filing referenced 'impact of weather on agriculture and food production' and 'identification and integration of acquisitions' in risk factors; these do not appear in newer filing's expanded list
- Older filing contained paragraph regarding fiscal year 2025 genomics restructuring and companion animal market weakness that does not appear in newer filing
- Older filing's statement 'We continue to evaluate the nature and extent of these issues and their impact on our business' and 'We expect these issues to continue to impact us in fiscal year 2026' are not present in newer filing
- Reworded:
- Older filing stated 'Also in fiscal year 2025' while newer filing states 'Also, in fiscal years 2025 and 2026'
- Older filing: 'have and may continue to increase' while newer filing: 'have increased, and may continue to increase'
- Older filing: 'signs of sequential improvement from prior quarters in certain key product lines' while newer filing: 'signs of sequential improvement from prior quarters and expectations for growth in calendar year 2026'
- Older filing's risk factors list includes 'global business disruption caused by the Russia invasion in Ukraine and related sanctions' whereas newer filing's more general reference is 'risks associated with international operations'
- Older filing stated 'These have and may continue to increase' regarding tariffs while newer filing states 'These have increased, and may continue to increase'
- Notes:
- The newer filing text appears truncated at the end of the Food Safety and Animal Safety discussion, limiting complete comparison of final portions
- Both filings are quarterly reports for different interim periods (three and six months ended November 30, 2025 vs November 30, 2024), which may account for some differences in forward-looking risk factor updates
Risk Factors
- Added:
- Newer filing (2026-04-09) reports financial data for nine months ended February 28, 2026, compared to older filing (2026-01-08) which reported six months ended November 30, 2025
- Newer filing shows February 28, 2026 balance sheet date; older filing shows November 30, 2025 balance sheet date
- Newer filing financial statements use millions format; older filing uses thousands format
- Newer filing includes comparison periods for nine months ended February 28, 2026 vs. February 28, 2025; older filing shows six months ended November 30, 2025 vs. November 30, 2024
- Removed:
- Older filing's Condensed Consolidated Statements of Cash Flows (unaudited) section not present in newer filing excerpt
- Older filing balance sheet dated November 30, 2025 not in newer filing (replaced by February 28, 2026)
- Older filing's six-month period statements replaced by nine-month period statements in newer filing
- Reworded:
- Presentation format changed from thousands to millions in the newer filing
- Balance sheet comparison changed from November 30, 2025 / May 31, 2025 to February 28, 2026 / May 31, 2025
- Income statement periods changed from 'three months ended November 30' and 'six months ended November 30' to 'three months ended February 28' and 'nine months ended February 28'
- Equity statement now shows progression through August 31, 2025 and November 30, 2025 before reaching February 28, 2026 in newer filing
- Notes:
- The two filings represent different interim periods (Q2 2026 vs. Q1 2026) with different comparison structures, making direct financial metric comparison problematic
- Unit presentation changed from thousands to millions, requiring conversion for comparison
- Newer filing excerpt provided does not include the actual Risk Factors section text, only table of contents reference
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-041 buy ($4370) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-041 buy ($4370) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NEOG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NEOG as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 45,045,067
- Reported value $404,955,151
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NEOG's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NEOG had 11,168,684 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NEOG had 5.12% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.53 days to cover at the same settlement.
- Reported short interest (shares) 11,168,684
- Short interest (% of shares outstanding) 5.12%
- Prior settlement (shares) 10,582,185
- Reported change 5.54%
- Days to cover (reported) 4.53
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- IDEXX Laboratories (IDXX)
- Thermo Fisher Scientific (TMO)
- Zoetis (ZTS)
- Bio-Rad Laboratories (BIO)
- Merck Animal Health (MRK)
- Elanco Animal Health (ELAN)
- PerkinElmer (PKI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NEOG vs…
Frequently asked questions
What does NEOGEN CORP (NEOG) do?
Neogen Corporation provides diagnostic test kits, services, and software focused on food and animal safety. Its Food Safety segment offers solutions for detecting foodborne pathogens, allergens, and spoilage organisms, while its Animal Safety segment supplies veterinary instruments, pharmaceuticals, genomics testing, and biosecurity products. The company serves food and feed producers, veterinary professionals, and laboratories globally.
What sector is NEOGEN CORP (NEOG) in?
NEOGEN CORP (NEOG) is classified in the Health Care sector. Its industry is Food and Animal Safety Diagnostics. It trades on NASDAQ.
Who are NEOGEN CORP's (NEOG) competitors?
Notable peers of NEOGEN CORP (NEOG) include IDEXX Laboratories, Thermo Fisher Scientific, Zoetis, Bio-Rad Laboratories and Merck Animal Health. This peer set is informational only — not financial advice.
Is NEOGEN CORP (NEOG) overbought or oversold right now?
NEOGEN CORP (NEOG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NEOG come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.